Cantor Fitzgerald Weighs in on Kura Oncology FY2025 Earnings

Kura Oncology, Inc. (NASDAQ:KURA) – Research analysts at Cantor Fitzgerald boosted their FY2025 earnings per share estimates for Kura Oncology in a research report issued on Wednesday, March 19th. Cantor Fitzgerald analyst L. Watsek now anticipates that the company will earn ($2.21) per share for the year, up from their prior estimate of ($2.94). Cantor Fitzgerald currently has a “Strong-Buy” rating on the stock. The consensus estimate for Kura Oncology’s current full-year earnings is ($2.44) per share.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.43. The company had revenue of $53.88 million for the quarter, compared to analysts’ expectations of $57.96 million.

Other research analysts also recently issued research reports about the stock. BTIG Research downgraded shares of Kura Oncology from a “buy” rating to a “neutral” rating in a research note on Thursday, February 6th. UBS Group decreased their price objective on shares of Kura Oncology from $27.00 to $14.00 and set a “buy” rating for the company in a research report on Thursday, March 6th. JMP Securities reissued a “market outperform” rating and issued a $28.00 target price on shares of Kura Oncology in a report on Thursday, February 6th. Wedbush reaffirmed an “outperform” rating and set a $36.00 price objective on shares of Kura Oncology in a research report on Thursday, February 27th. Finally, StockNews.com downgraded Kura Oncology from a “buy” rating to a “hold” rating in a report on Tuesday. Four equities research analysts have rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $25.50.

Kura Oncology Stock Performance

Shares of Kura Oncology stock opened at $7.84 on Friday. The business has a 50-day simple moving average of $7.82 and a 200-day simple moving average of $12.49. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. Kura Oncology has a one year low of $6.79 and a one year high of $23.48. The company has a market cap of $633.12 million, a PE ratio of -3.32 and a beta of 0.85.

Insider Activity

In other Kura Oncology news, insider Mollie Leoni sold 4,963 shares of Kura Oncology stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $39,058.81. Following the transaction, the insider now owns 88,253 shares of the company’s stock, valued at $694,551.11. The trade was a 5.32 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Thomas James Doyle sold 4,949 shares of the business’s stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $38,948.63. Following the completion of the sale, the senior vice president now owns 88,193 shares of the company’s stock, valued at approximately $694,078.91. This represents a 5.31 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 11,729 shares of company stock valued at $92,307. Insiders own 5.50% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of KURA. Suvretta Capital Management LLC raised its holdings in shares of Kura Oncology by 8.2% in the third quarter. Suvretta Capital Management LLC now owns 7,652,782 shares of the company’s stock valued at $149,535,000 after buying an additional 583,155 shares during the last quarter. Vanguard Group Inc. increased its position in Kura Oncology by 14.6% in the 4th quarter. Vanguard Group Inc. now owns 4,818,898 shares of the company’s stock valued at $41,973,000 after acquiring an additional 615,211 shares during the period. RA Capital Management L.P. purchased a new stake in Kura Oncology during the 4th quarter valued at approximately $38,769,000. Millennium Management LLC lifted its position in Kura Oncology by 180.1% during the 4th quarter. Millennium Management LLC now owns 2,367,148 shares of the company’s stock worth $20,618,000 after acquiring an additional 1,521,954 shares during the period. Finally, Geode Capital Management LLC grew its stake in shares of Kura Oncology by 2.4% in the 3rd quarter. Geode Capital Management LLC now owns 1,780,509 shares of the company’s stock valued at $34,798,000 after purchasing an additional 41,535 shares during the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.